Viropil

Viropil is a combination antiretroviral medication used in the management and treatment of HIV-1 infection. This fixed-dose combination includes three active ingredients: dolutegravir, lamivudine, and tenofovir disoproxil fumarate. Each of these components works synergistically to control HIV replication and improve immune function.

Composition:

• Dolutegravir: 50 mg
• Lamivudine: 300 mg
• Tenofovir Disoproxil Fumarate: 300 mg

Uses:

Viropil is used for:

• The treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg.
• It is part of a comprehensive antiretroviral therapy (ART) regimen intended to suppress viral load and improve immune system function.

Mechanism of Action:

Dolutegravir:

• An integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, preventing the integration of viral DNA into the host cell genome. This step is crucial for viral replication.

Lamivudine:

• A nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase enzyme. This enzyme is essential for the conversion of viral RNA into DNA, a critical step in the HIV replication process.

Tenofovir Disoproxil Fumarate:

• Another NRTI that works similarly to lamivudine by blocking the reverse transcriptase enzyme, preventing the replication of the virus.

Dosage:

• Adults and Adolescents (weighing at least 40 kg): One tablet taken orally once daily with or without food.

Side Effects:

Common side effects:

• Headache
• Nausea
• Diarrhea
• Insomnia
• Fatigue
• Dizziness

Less common but serious side effects:

• Lactic acidosis
• Hepatomegaly with steatosis (enlarged liver with fat)
• Severe liver problems
• Renal (kidney) impairment
• Bone density loss

Recommendations:

• Take Viropil exactly as prescribed by your healthcare provider.
• Do not miss doses or adjust the dose on your own.
• Take the medication at the same time every day to maintain consistent drug levels.
• Inform your healthcare provider about any other medications or supplements you are taking to avoid possible drug interactions.

Important Note:

• Do not stop taking Viropil without consulting your healthcare provider, as this may lead to viral resistance and treatment failure.
• Regularly monitor kidney function and bone mineral density if you are at risk for renal impairment or osteopenia/osteoporosis.
• Pregnant women or those planning to become pregnant should inform their healthcare provider to discuss the potential risks and benefits.
• Store the medication at room temperature, away from moisture and direct light.
• Keep all medical appointments and undertake regular blood tests to monitor your overall health and treatment progress.
• Use effective contraception to prevent pregnancy during treatment, and if you become pregnant, inform your healthcare provider immediately.

This information covers the key aspects of Viropil (Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate). For any specific concerns or questions, always consult your healthcare provider.